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Comparison of the Antileukemic Activity In Vitro of Dexamethasone and 
Prednisolone in Childhood Acute Lymphoblastic Leukemia
G.J.L. Kaspers, m d, PhD, A.J.P. Veerman, m d, phd, C  Popp-Smjders, PhD, 
M. Lomecky, bsc, C.H. Van Zantwijk, L.M.J.W. Swinkels, PhD, 
E.R. Van Wering, m d, PhD, and R. Pieters, m d, phd, m sc
It is generally assumed that prednisolone 
(PRD) and dexamethasone (DXM) have equal 
glucocorticoid activity if PRD is given at sev­
enfold higher doses. Resuits of clinical studies of 
childhood acute lymphoblastic leukemia (ALL) 
suggested that DXM is more potent relative to 
PRD than assumed. The purpose of this study 
was to determine the relative antileukemic activ­
ity of PRD phosphate and DXM phosphate in 
133 untreated childhood ALL samples in vitro, 
using the 3-(4,5-dimethylthiazol-2~y!)-2,5~di- 
phenyltetrazolium-bromide (MTT) assay, There 
was a marked variation in antileukemic activity 
of both agents among the patient samples. The 
median LC50 (drug concentration lethal to 50% 
of the ALL cells) for PRD phosphate was 3.50  
|jlM, for DXM phosphate 0,20 jxM. The individu­
ally calculated ratios oftheLCSO values for PRD
and DXM phosphate showed a large range from
0.7 to > 5 0 0 ; with a median of 16.2. This 16-fold 
difference could not be explained by differences 
between these glucocorticoids in stability, hy­
drolysis into unesterified drug, adhesion to the 
wall o f the microculture plates, or protein bind­
ing. ALL cells were cross-resistant to PRD and 
DXM phosphate (correlation coefficient =
0.85, P <  0.000001).
W e conclude that the in vitro antileukemic 
activity o f DXM phosphate is median 16-fold 
higher than that of PRD phosphate, which 
contrasts to the generally assumed factor of
7, Based on the higher potency of DXM, 
and its more favorable pharmacokinetics as 
reported in the literature, DXM may be pre­
ferred to PRD as the glucocorticoid in the 
treatment of ALL. © 1996 wiiey-Uss, inc.
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INTRODUCTION
Glucocorticoids .are effective drugs in the treatment of 
acute lymphoblastic leukemia (ALL). Response rates to 
single-agent glucocorticoid treatment range from 75-90% 
in newly diagnosed childhood ALL [1]. Prednisolone 
(PRD) is the most frequently used glucocorticoid, but 
few studies addressed the question whether other gluco­
corticoids, such as dexamethasone (DXM), might be of 
more value. It is assumed that DXM is seven times more 
potent than PRD, or in other words, PRD and DXM 
would have equal antileukemic activity if PRD is given 
at sevenfold higher doses. However, this assumption is 
not based on a comparison of the antileukemic activity 
of both agents, but rather on their antiinflammatory and 
thymolytic activities [2 ]. Results of two clinical studies 
showed that treatment results with DXM as part of a 
combination chemotherapy for leukemias were better than 
those with PRD, although “equivalent1' doses were used 
[3,4]. The pharmacokinetics of DXM seem to be more 
favorable than those of PRD [5-7]. It may also be that 
DXM is more potent than is assumed.
The purpose of the present study was to compare the
© 1996 Wiley-Liss, Inc.
in vitro antileukemic activity of PRD and DXM phosphate 
in childhood ALL, using the 3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazalium-bromide (MTT) assay. We also 
studied several aspects of their in vitro behavior— 
stability, hydrolysis, adhesion to plastic, and protein bind­
ing— to minimize the possibility of differences in the 
relative antileukemic activities of these glucocorticoids 
caused by artefacts. The MTT assay is an objective and 
reliable cell culture drug resistance assay suited for large- 
scale testing of leukemia and lymphoma samples [8,9]. 
Using this assay, we previously reported significant corre-
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lations between the in vitro antileukemic activity o f PRD 
with the clinical response to a prednisone monotherapy 
[1 0 ], and with the clinical outcome after combination 
chemotherapy in childhood ALL [11].
MATERIALS AND METHODS 
Samples and Patients
Bone marrow (BM) and peripheral blood (PB) samples 
as well as smears from children with newly diagnosed 
non-B ALL were sent by local institutions to the labora­
tory of the Dutch Childhood Leukemia Study group 
(DCLSG) for confirmation of diagnosis, classification 
according to the FAB criteria [12], and immunophenotyp- 
ing [13]. Mononuclear cells were isolated by Ficoll den­
sity gradient centrifugation (Ficol Paque; density 1.077 
g/ml; Pharmacia, Sweden). Until October 1, 1991, immu­
nofluorescence was used for terminal deoxynucleotidyl- 
transferase (TdT) and surface immunoglobulin heavy 
chain, while an indirect immunoperoxidase staining tech­
nique on cytocentrifuge preparations was used for all 
other antibodies. From October 1, 1991 onwards, immu­
noperoxidase staining was replaced by flow cytometry 
after calibrating these techniques.
Samples from 159 patients were sent by the DCLSG 
laboratory to the research laboratory for pediatric hemato- 
onco-immunology of the Free University Hospital in Am ­
sterdam for drug resistance testing, with informed con­
sent. Samples from 133 (84%) of the 159 children with 
non-B ALL were successfully tested. A minority (n =  60) 
of these samples was included in a preliminary meeting 
report [14]. Twenty-six assays could not be evaluated 
because of infection (n =  1), laboratory error (n =  1), 
insufficient cells in the sample submitted (n =  3), per­
centage of leukemic cells below 70% after 4 days of 
culture (n =  9), and failure of ALL cells to reduce MTT 
into formazan in the drug-free control wells (n =  1 2 ).
The median age of the 74 male and 59 female patients 
was 5 years (range 0-15 years). The white blood cell 
count at diagnosis ranged from 2.5 to 900 X lOVl (median 
25.8 X 10tJ/l). Three cases could not be classified morpho­
logically, while 103 cases were diagnosed as FAB type 
LI and 27 as FAB L2. Of 132 immunophenotyped ALL 
cases, 6  were pro-B ALL (positive for TdT, CD19, and 
HLA-DR), 97 were common- or pre-B ALL (positive for 
TdT, CD19, and HLA-DR, and positive for CD 10 or 
cytoplasmic (x), and 29 T-ALL (positive for TdT, CD3, 
and CD7).
Reagents and Drugs
PRD and DXM sodium phosphate and acidified isopro- 
panol were obtained from the hospital pharmacy, which 
purchased the glucocorticoids from Hyocint (Oss, The 
Netherlands). PRD phosphate was dissolved in saline,
TABLE I. Antileukemic Activity of PRD and DXM Phosphate
In Vitro in Untreated ALL Samples.
LC50 values ( jjlM )  and individual ratios
Median Range na
PRD phosphate 3.50 < 0 .13  to > 4 1 6 7 130
DXM  phosphate 0.20 < 0 .0005  to > 1 5 .3 114
Individual ratios of 16.2 0.7 to > 5 0 0 74
LC50 PRD/DXM
nBoth drugs were tested successfully in 111 samples, but individual 
ratios o f the LC50 for PRD phosphate divided by the LC50 for DXM  
phosphate could not be calculated in 37 cases, because one (n =  21) 
or both (n =  16) LC50 values were outside the concentration ranges 
tested (if both, always at the same end of the ranges).
o Individual 
ratios
+ Median ratio 
16.2
Fig. 1. Ratio of LC50 values for PRD and DXM  phosphate in 74 
untreated childhood ALL samples.
whereas DXM phosphate was obtained in solution in 
ampules as used in patients. Solvents for DXM phosphate 
were sodium pyrosulfate (1 mg/ml), sodium edetate (0.5 
mg/ml), glycerol 85% (0.15 ml/ml), and sodium hydrox­
ide 2N (2 |xl/ml). These solvents were not cytotoxic nor 
did they influence the background of the culture medium 
in these concentrations.
Cells were cultured in RPMI 1640 (Dutch modifica­
tion, Gibco, Uxbridge, UK) containing 20% heat-inacti­
vated fetal calf serum, 2 mM L-glutamine, 100 IU/ml 
penicillin, 100  |xg/ml streptomycin, 0.125 jxg/ml fun­
gizone, 200 jjug/ml gentamycin, all obtained from Flow 
Laboratories (Irvine, UK), and 5 |Jig/ml insulin, 5 fxg/ml 
transferrin, and 5 ng/ml sodium selenite, obtained from 
Sigma. MTT was also obtained from Sigma.
MTT Assay
This cell culture drug resistance assay was started 
within 36 hours after collection of the sample. BM 
and PB samples were evaluated together, because they 
do not differ in drug resistance [15]. All samples tested 
with the MTT assay contained >80%  leukemic cells 
(as percentage of all viable cells) at the start of the 
assay, and results were considered evaluable in case 
of >70% .leukemic cells after culture. In addition, the 
minimum mean optical density (OD) of the six control
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in humidified air containing 5% C 0 2 for 4 days at 37°C. 
Then 10 jxl MTT solution (5 mg/ml) was added and after 
shaking the plates until the cell pellet was resuspended, 
they were incubated for 6  hours. The formazan crystals 
formed were dissolved with 1 0 0  jjlI acidified isopropanol. 
The OD of the wells, which is linearly related to the cell 
number [17], was measured with an EL-312 microplate 
spectrophotometer (Bio-tek Instruments Inc., Winooski, 
USA) at 562 nm. After correction for the background 
color of the medium, leukemic cell survival (LCS) was
LCS =  (OD treatedcalculated
0.030.1 1 10 100 1000
LC50 prednisolone (uM)
Fig. 2. Correlation between LC50 values for PRD and DXM phos 
phate in untreated childhood ALL samples.
by the equation: 
well/mean OD control wells) X 100%, followed by aver­
aging the two measurements at each concentration. The 
LC50, the drug concentration lethal to 50% of the 
cells, was used as the measure of resistance, and was 
calculated using the two concentrations from the dose- 
response curve which gave an LCS just above and be­
low 50%.
TABLE II. Som e Aspects o f the In Vitro Behavior o f PRD and  
DXM  in Our Assay System In Vitro Behavior of PRD and DXM Phosphate
Functional stability of PRD and DXM phosphate was 
studied by repeated testing of cryopreserved cells from 
the same patients, using stock solutions which had been 
stored at —20°C between 2 months and 3 years, and in 
separate experiments using plates with these drugs in the 
wells stored at -20°C  for 1-6 months.
Hydrolysis of PRD and DXM phosphate into unesteri- 
fied glucocorticoid in culture medium as described above 
was studied at the laboratory of the Department of Endo­
crinology of the Free University Hospital in Amsterdam, 
wells (see later) was 0.050. These criteria ascertain concentrations of PRD and DXM phosphate, and
PRD DXM
Phosphates
Functionally stable after storage Yes Yes
of at least 6 months
Hydrolysis into unesterified 10-15% 10-15%
glucocorticoid
Unesterified
Adhesion to polystyrene No No
Protein binding 22.2% 21.6%
reliable assay results [8,16]. unesterified PRD and DXM, were determined without
The MTT assay was performed at the research labora- prior extraction by high-performance liquid chromatogra- 
tory for pediatric hemato-onco-immimology of the Free phy (HPLC) and ultraviolet (UV) detection (254 nm),
University Hospital. AnJSO jxl^  cell suspension (2 X 10 both before and after the 4 days of culture. The four
compounds were separated completely, using an injection 
volume of 100 pi; column C l 8  reversed phase microsph­
ere 3 fjum, 50 X  4.6 mm (Chrompack, The Netherlands); 
mobile phase methanol:water:acetic acid (40:58:2), 0.01 
M tetrabutylammoniumsulphate, pH =  4.
Protein binding and adhesion to polystyrene— the ma-
cells/ml) was added to 20 jxl of the drug solutions in 96- 
well (12 columns, 8 rows) microculture plates. These 
plates had been prepared before use and were stored at 
-20°C  for not longer than 6  months. Each drug was 
tested in duplicate in six concentrations, which ranged 
from 0.13 jjlM to 4.2 mM for PRD (eightfold dilutions) 
and from 0.5 nM to 15.3 jjlM for DXM (also eightfold
dilutions). These concentrations include clinically achiev- ^  which the microculture plates are m ad e-w ere  
able peak and steady state plasma levels. Because evapo- stu^ied at the laboratory of the Department of Experimen- 
ration had been observed from the outer wells, these were an<^  Chemical Endocrinology of the St. Radboud Uni­
filled with RPMI only. Thus, columns 1 and 12 and rows versity Hospital in Nijmegen, using an equilibrium dial- 
1 and 8 were not used. Columns 2 and 3S 6  and 7, 8 and as^  previously described [18]. For these 
9, and 10 and 11 contained four different drugs, with experiments, tritiated unesterified PRD (Amersham TRK- 
duplicates of all concentrations on the same row, and 691, 2.44 Ci/mmol) and DXM (Amersham TRK-417,
1.70 TBq/mmol) were used, and measurements were done 
in duplicate. Protein binding was measured after an incu-
with the higher concentrations in the upper rows, and the 
lower concentrations in the lower rows. Columns 4 and 
5 contained in the upper six wells culture medium only bation of 30 minutes, and adhesion to polystyrene after
to assess the background color of the medium, and in the an incubation of up to 6  hours (times at which a plateau
lower six wells cells in medium without drugs to deter­
mine the control cell survival. The plates were incubated
had been reached). These experiments were performed 
in culture medium as described above.
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TABLE III. A Summary of Studies About the Relative Activities of PRD and DXM
Activity of
Reference Model Effect DXM/PRD
22 Fibroblasts Growth inhibition 4
23 Human Antirheumatic 8
24 Rat Antiinflammatory 48
Thymolysis 48
25 Thymus cells Induction of pyknosis in vitro 11
26 Lymphocytes Inhibition of PHA-induced stimulation 10
27 Rat Depletion of glucocorticoid receptor 10
28 Lymphocytes Immunosuppression in vitro 4
29 Rat Antiinflammatory 39
Thymolysis 12
Glycogenesis 18
30 Human Pituitary-adrenal function suppression 16
31 Mice Inhibition o f tumor induction and promotion 67
32 Rat Glycogenesis 36
Antiinflammatory 68
33 Human Pituitary-adrenal function suppression 40
34 Rat Antiinflammatory 240
Thymolysis 69
Adrenal suppression 218
Glycogenesis 90
35 Rheumatoid synovial tissue Prostaglandin production 3
36 Rat Glycogenesis 6
Antiinflammatory 60
37 Mouse thymocytes DNA fragmentation 100
38 Mice Antiinflammatory 5
Mice Thymolysis 26
Mice Eosinipenia 3
Dogs Eosinipenia 5
Rat Diuretic 10
39 Rat Antiinflammatory 12
Rat Thymolysis 20
40 Rat Dermal atrophy 4
Rat Antiinflammatory 10
Statistics
The Mann-Whitney U test for paired and unpaired data 
and the Spearman's rank correlation test (parameter, Rho) 
were used for two-tailed testing at a level of significance 
of P = 0.05.
RESULTS 
MTT Assay
For 133 successful assays, the percentage leukemic 
cells in the control wells was median 94% at the start of 
the culture, and 89% at the end of the 4-day incubation 
period (percentages of the total number of viable cells). 
The coefficient of variation of the six control wells after 
4 days of culture was median 5.2% (range 0.9-15.3%). 
The intra-assay (duplicates) and interassay (repeated test­
ing of same frozen sample) variation in LC50 values was 
less than a factor of 5 for both PRD and DXM phosphate, 
which is well within one dilution factor of 8 .
Relative Antileukemic Activity of PRD and 
DXM Phosphate
For both drugs, the LCS was generally dose related, 
but a wide concentration range (4-log) was necessary to 
obtain dose-response curves. The dose-response curves 
tended to be more steep with DXM, and plateaus in the 
antileukemic activity were more often seen with PRD. 
However, because of a very strong cross-resistance 
(Rho >  0.95) between LC50 values and area under the 
dose-response curves for both drugs, the LC50 was used 
as the well-known parameter. Table I shows the median 
and ranges of LC50 values, which were known for both 
drugs in 111 cases. For each drug, the LC50 values dif­
fered more than 1,000-fold between patients. Based on 
the group median LC50 values, DXM phosphate had a 
17-fold higher antileukemic activity than PRD phosphate. 
Table I also shows the median and range of the individual 
ratios of the LC50 values for these glucocorticoids, which 
could be calculated for 74 individual samples (shown in 
Fig. 1). DXM phosphate was 16.2-fold more potent than
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CHoOH
I
C - 0
CHnOH
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After 4 days of culture at 37°C, the glucocorticoid 
phosphates had been hydrolyzed into their corresponding 
unesterified forms to an extent of 15% at most. No differ­
ence in this percentage was found between PRD and 
DXM phosphate or between incubation with and with­
out cells.
There was no significant adhesion of unesterified PRD 
or DXM to polystyrene after incubation up to 6  hours, 
as was demonstrated by the unchanged radioactivity of the 
tritiated glucocorticoids detected in the culture medium. 
Protein binding of unesterified PRD and DXM, at concen­
trations in the nanomolar or lower range, in culture me­
dium as described above was mean 22.3% for PRD (dupli­
cates 22.0 and 22.5%) and 21,6% for DXM (duplicates 
21.2 and 22.0%). In the same medium, but without fetal 
calf serum, this binding was only 8.0% for PRD and 
10.1% for DXM. Table II summarizes the results with 
respect to the in vitro behavior of PRD and DXM.
c h 2oh
Ic=o
DEXAMETHASONE
Fig. 3. Chemical structures of cortisol and of the synthetic glucocorti­
coids PRD and DXM.
PRD phosphate based on these individual numbers. In 
16 (22%) of 74 patients this ratio was even more than 
50. An absolute ratio could not be calculated in 16 cases 
because both LC50 values were outside the concentration 
ranges used (always at the same end of these ranges), 
and not in 21  cases because one LC50 value was outside 
the concentration range used. Including the latter group 
in the analysis (a ratio of >190 was included as 190) 
did not influence the results: median ratio 15.8, range
0.7->500. Clinical and cell biological features were not 
significantly related to the ratio of LC50 values for PRD 
and DXM (not shown).
ALL cells were highly significantly cross-resistant to 
PRD and DXM phosphate (Fig, 2). The correlation coeffi­
cient for the LC50 values for both agents was 0.85 
(P <  0.000001). This pattern was also found within sev­
eral subgroups distinguished by FAB- or immunopheno- 
type (not shown).
In Vitro Behavior of PRD and DXM Phosphate
PRD and DXM phosphate were functionally stable 
over the time period of 3 years studied. Thus» the antileu­
kemic activity of both drugs did not decrease in time 
when stored in stock solutions or in microculture plates.
DISCUSSION AND CONCLUSIONS
Single-agent glucocorticoid treatment in newly diag­
nosed ALL results in a response rate of approximately 
80%. At present, PRD is the most frequently used gluco­
corticoid in the first-line treatment of ALL, but few stud­
ies have compared the antileukemic activity of PRD with 
that of other glucocorticoids, such as DXM. Recently, 
results of two studies which addressed this question have 
been reported. PRD and DXM were used at what is gener­
ally considered equivalent doses, 40 mg/m2 and 6  mg/m2 
daily, respectively. In a randomized study, Jones et al.
[3] reported a significant reduction in central nervous 
system (CNS) relapses, but not in BM relapses, when 
DXM was substituted for PRD in the treatment of child­
hood ALL. Veerman et al. [4] reported the results of the 
Dutch ALL-VI protocol in which DXM was used, but 
which was preceded by a pilot study in which the only 
difference was the use of PRD instead of DXM. With 
DXM, the complete remission rate was higher and less 
relapses were observed both in the BM and in the CNS. 
The toxicity of DXM seemed to be more pronounced 
than that of PRD.
One explanation for the better CNS results with DXM 
has been provided by Balis et al. [5], who reported that 
in monkeys DXM had more favorable cerebrospinal fluid 
(CSF) pharmacokinetics than PRD. The half-life of DXM 
in the CSF was 1.5-fold longer, and the CSF:plasma ratio 
for DXM was 2-fold higher than for PRD. In addition, 
the plasma half-life of DXM is longer than that of PRD 
[19-22]. In summary, the pharmacokinetics of DXM are 
more favorable than those of PRD [5-7].
An additional explanation for the better results with 
DXM, investigated in the present study, may be that DXM 
has a higher cellular antileukemic activity compared to 
that o f PRD than is generally assumed. Indeed, we found
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that the antileukemic activity of DXM phosphate in vitro 
was 16-fold higher than that of PRD phosphate, which 
contrasts to the generally assumed factor of 7. We studied 
several aspects of the in vitro behavior of glucocorticoids, 
in order to minimize the possibility of the contribution 
of in vitro artefacts to this ratio of 16 (Table II). No 
differences between the two glucocorticoids were ob­
served.
An extensive literature study did not reveal the source 
of the assumption that equivalent doses of PRD are seven 
times higher than those of DXM in the treatment o f ALL. 
Apparently, the factor of 7 has been extrapolated from 
studies in which PRD and DXM were compared regarding 
other effects, such as their antiinflammatory or thymolytic 
potential. However, even these studies, summarized in 
Table III, do not support this factor of 7 [23-41]. Ratios 
from 3 up to 240 were found in various systems, mostly 
studying animals rather than human subjects. DXM was 
often more than sevenfold more potent than PRD.
It is unknown why DXM is more potent than PRD. 
These glucocorticoids are synthetic analogs of cortisol, 
and their molecules differ in only a few, although im­
portant, aspects (Fig. 3). Several authors reported that the 
glucocorticoid receptor of leukemic cells has a higher 
affinity for DXM than for PRD [42-45], but this affinity 
has also been reported to be similar [46] or even higher 
for PRD [47]. Icchii et al. [48] reported that the DXM- 
receptor complex was more stable than the PRD-receptor 
complex. The difference in potency between DXM and 
PRD might also be partly explained by a direct relation 
between the specific steroid nested in the steroid-receptor 
complex and events occurring at the postreceptor level
[49].
We found that untreated ALL cells were significantly 
cross-resistant to PRD and DXM. This pattern was also 
found in our studies in childhood relapsed ALL and in 
childhood acute nonlymphoblastic leukemia [50,51]. 
Therefore, DXM should probably not be considered as a 
glucocorticoid which might circumvent PRD resistance. 
A more promising drug in this respect is cortivazol, a 
glucocorticoid which binds the glucocorticoid receptor at 
two sites, while PRD and DXM bind at only one site. A 
human leukemic cell line has been described which was 
resistant to DXM, but not to cortivazol [52].
In conclusion, the in vitro antileukemic activity of 
DXM phosphate was 16-fold higher than that of PRD 
phosphate in childhood ALL, with marked interindividual 
differences. Of course, our in vitro study does not consider 
several clinically important pharmacokinetic aspects of 
these drugs and therefore cannot give the final answer to 
the question whether DXM is more potent than assumed. 
However, two clinical studies in childhood ALL showed 
that DXM, at so-called equivalent doses, gave better treat­
ment results than PRD. We suggest that DXM is to be 
preferred to PRD as a glucocorticoid in the treatment of
ALL, because of its higher potency, and because of its 
more favorable pharmacokinetics. However, a greater an­
tileukemic activity of DXM could be associated with 
increased toxicity and increased drug interactions. Clini­
cal studies are warranted to address the important ques­
tion: Which glucocorticoid should be preferred in the 
treatment of ALL?
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